Cipla Limited has reported its highest-ever quarterly revenue of ₹7,073 crore in Q3 FY25, reflecting an 8% year-on-year (YoY) growth. The company’s EBITDA stood at ₹1,989 crore, marking a 16% YoY increase, with an EBITDA margin of 28.1%. Net profit (PAT) surged 50% YoY to ₹1,571 crore, with a PAT margin of 22.2%.
The growth was driven by strong performance across key markets. Cipla’s India business saw 10% YoY growth, led by branded prescription and trade generics. North America posted a quarterly revenue of $226 million, supported by traction in differentiated assets. Emerging markets and Europe registered 20% revenue growth in USD terms, while Africa’s prescription business maintained its top market ranking with 9% revenue growth in USD terms.
Cipla’s R&D investments stood at ₹360 crore, accounting for 5.1% of total sales, focused on product filings and development. The company’s net cash position remained strong at ₹8,947 crore, with debt primarily comprising lease liabilities and working capital needs.
The company’s strong financial performance underscores its ability to maintain steady growth across geographies and product segments, reinforcing its market leadership in key therapeutic areas.